UY30530A1 - Forma farmacologica peroral para la anticoncepcion - Google Patents

Forma farmacologica peroral para la anticoncepcion

Info

Publication number
UY30530A1
UY30530A1 UY30530A UY30530A UY30530A1 UY 30530 A1 UY30530 A1 UY 30530A1 UY 30530 A UY30530 A UY 30530A UY 30530 A UY30530 A UY 30530A UY 30530 A1 UY30530 A1 UY 30530A1
Authority
UY
Uruguay
Prior art keywords
peroral
dienogest
alpha
conception
daily dosage
Prior art date
Application number
UY30530A
Other languages
English (en)
Inventor
Sabine Fricke
Herbert Wiesinger
Ralf Ladwing
Hagen Gerecke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30530A1 publication Critical patent/UY30530A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una forma farmacologica peroral para la anticoncepcion contiene como un componente de principio activo 17a(alfa)-cianometil-17-B-hidroxiestra-4,9-dien-3-ona (dienogest) en una dosificacion diaria de igual o menor que 2,0 mg y como otro componente de principio activo 17a(alfa)-etinilestradiol (etinilestradio) en una dosificacion diaria menor que 0,03 mg junto con uno o varios vehículos de aceptacion farmacéutica. El principio activo dienogest está contenido en forma cristalina con un tamano de partícula promedio de 25 a 70 um. El principio activo etinilestradiol se incorpora en forma micronizada o como solucion etanolica durante la granulacion.
UY30530A 2006-08-10 2007-08-07 Forma farmacologica peroral para la anticoncepcion UY30530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06016694A EP1886694B1 (de) 2006-08-10 2006-08-10 Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption

Publications (1)

Publication Number Publication Date
UY30530A1 true UY30530A1 (es) 2008-03-31

Family

ID=37561777

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30530A UY30530A1 (es) 2006-08-10 2007-08-07 Forma farmacologica peroral para la anticoncepcion

Country Status (18)

Country Link
EP (1) EP1886694B1 (es)
AR (1) AR062323A1 (es)
AT (1) ATE432714T1 (es)
CL (1) CL2007002323A1 (es)
CY (1) CY1110348T1 (es)
DE (1) DE502006003892D1 (es)
DK (1) DK1886694T3 (es)
DO (1) DOP2007000122A (es)
ES (1) ES2327665T3 (es)
HR (1) HRP20090438T1 (es)
NO (1) NO20091057L (es)
PE (1) PE20080541A1 (es)
PL (1) PL1886694T3 (es)
PT (1) PT1886694E (es)
SI (1) SI1886694T1 (es)
TW (1) TW200817012A (es)
UY (1) UY30530A1 (es)
WO (1) WO2008017331A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
CN115487198B (zh) * 2022-09-20 2024-01-02 华中药业股份有限公司 一种快溶出度的左炔诺孕酮制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
TW200817012A (en) 2008-04-16
WO2008017331A2 (de) 2008-02-14
EP1886694A1 (de) 2008-02-13
DE502006003892D1 (de) 2009-07-16
CY1110348T1 (el) 2015-04-29
DOP2007000122A (es) 2008-02-15
EP1886694B1 (de) 2009-06-03
PE20080541A1 (es) 2008-07-10
SI1886694T1 (sl) 2009-10-31
NO20091057L (no) 2009-03-09
AR062323A1 (es) 2008-10-29
HRP20090438T1 (en) 2009-09-30
PT1886694E (pt) 2009-08-17
CL2007002323A1 (es) 2008-02-15
ATE432714T1 (de) 2009-06-15
DK1886694T3 (da) 2009-09-28
WO2008017331A3 (de) 2009-01-08
ES2327665T3 (es) 2009-11-02
PL1886694T3 (pl) 2009-11-30

Similar Documents

Publication Publication Date Title
RS53876B1 (en) PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
UY29835A1 (es) Formas de dosificación farmacéutica sólidas que comprenden 5-cloro-n-(((5s)-2-oxo-3-(4-(3-oxo-4-morfolinil)fenil)-1,3-oxazolidin-5-il)metil)-2-tiofenocarboxamida
PE20142101A1 (es) Composiciones farmaceuticas de aliskiren
US20140348957A1 (en) Therapeutic and Method of Use
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
JP2010539153A5 (es)
UY30530A1 (es) Forma farmacologica peroral para la anticoncepcion
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
AR053545A1 (es) Preparacion farmaceutica para la anticoncepcion oral
CR10912A (es) Preparacion framaceutica para reducir la endometriosis
CR9240A (es) Forma farmacologica peroral solida para la anticoncepcion
CL2012000499A1 (es) Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485).
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
TH80558B (th) รูปแบบยาทางช่องปากชนิดแข็งสำหรับการคุมกำเนิด
PE20091695A1 (es) COMBINACION FARMACEUTICA DE DROSPIRENONA Y 17ß-ESTRADIOL
PE20090075A1 (es) Combinacion de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca
AR059678A1 (es) Composicion de trazodona para administracion una vez por dia
UY28181A1 (es) Una composición farmacéutica para ser usada como anticonceptivo
CU20090116A7 (es) Preparación farmacéutica para reducir la endometriosis
TH80558A (th) รูปแบบยาทางช่องปากชนิดแข็งสำหรับการคุมกำเนิด

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20090915